

Tomohiro Umezu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2453759/publications.pdf>

Version: 2024-02-01

49
papers

2,114
citations

430874

18
h-index

233421

45
g-index

52
all docs

52
docs citations

52
times ranked

3707
citing authors

#	ARTICLE	IF	CITATIONS
1	Acerola exosome-like nanovesicles to systemically deliver nucleic acid medicine via oral administration. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 21, 199-208.	4.1	46
2	Comprehensive Gene Analysis of IgG4-Related Ophthalmic Disease Using RNA Sequencing. <i>Journal of Clinical Medicine</i> , 2020, 9, 3458.	2.4	6
3	Comprehensive analysis of liver and blood miRNA in precancerous conditions. <i>Scientific Reports</i> , 2020, 10, 21766.	3.3	11
4	Predisposed genomic instability in pre-treatment bone marrow evolves to therapy-related myeloid neoplasms in malignant lymphoma. <i>Haematologica</i> , 2020, 105, e337-e339.	3.5	7
5	Effect of the extracellular component of bone marrow mesenchymal stromal cells from healthy donors on hematologic neoplasms and their angiogenesis. <i>Human Cell</i> , 2020, 33, 599-609.	2.7	10
6	Downregulation of extracellular vesicle microRNAâ€¹101 derived from bone marrow mesenchymal stromal cells in myelodysplastic syndrome with disease progression. <i>Oncology Letters</i> , 2020, 19, 2053-2061.	1.8	5
7	Maintenance 5-azacytidine therapy by MRD monitoring after allogeneic HSCT in myeloid/lymphoid neoplasms with FGFR1 rearrangement. <i>Bone Marrow Transplantation</i> , 2019, 54, 1148-1150.	2.4	3
8	<p>A novel non-invasive monitoring assay of 5-azacitidine efficacy using global DNA methylation of peripheral blood in myelodysplastic syndrome</p>. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 1821-1833.	4.3	3
9	Lineage-specific RUNX2 super-enhancer activates MYC and promotes the development of blastic plasmacytoid dendritic cell neoplasm. <i>Nature Communications</i> , 2019, 10, 1653.	12.8	34
10	Induction of multiple myeloma bone marrow stromal cell apoptosis by inhibiting extracellular vesicle miR-10a secretion. <i>Blood Advances</i> , 2019, 3, 3228-3240.	5.2	27
11	BIM deletion polymorphism accounts for lack of favorable outcome in Japanese females with follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 1283-1288.	1.3	3
12	Hidden <i>FLT3</i>-D835Y clone in <i>FLT3</i>-ITD-positive acute myeloid leukemia that evolved into very late relapse with T-lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 1490-1493.	1.3	2
13	Extracellular vesicle-mediated cellâ€“cell communication in haematological neoplasms. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2018, 373, 20160484.	4.0	30
14	Chromatin Regulation by HP1 ^{Î³} Contributes to Survival of 5-Azacytidine-Resistant Cells. <i>Frontiers in Pharmacology</i> , 2018, 9, 1166.	3.5	4
15	Stratification of mouse vaginal epithelium. 1. Development of 3 dimensional models in vitro with clonal cell linesâ€“. <i>Biology of Reproduction</i> , 2018, 99, 718-726.	2.7	8
16	Exosomal miRNA Signatures for Late-Onset Acute Graft-Versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2493.	4.1	17
17	Stratification of mouse vaginal epithelium 2. Identification of factors inducing stratificationâ€“. <i>Biology of Reproduction</i> , 2018, 99, 727-734.	2.7	4
18	Lineage-Specific RUNX2 Super-Enhancer Activates MYC Via Translocation (6;8) to Promote the Development of Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Blood</i> , 2018, 132, 761-761.	1.4	4

#	ARTICLE	IF	CITATIONS
19	Clonal Evolution of Therapy-Related Myeloid Neoplasm Analyzed Sequentially By Targeted Deep Sequencing Using Bone Marrow Cells. <i>Blood</i> , 2018, 132, 5525-5525.	1.4	0
20	Up-regulated exosomal miRNA-140-3p in CML patients with musculoskeletal pain associated with discontinuation of tyrosine kinase inhibitors. <i>International Journal of Hematology</i> , 2017, 105, 419-422.	1.6	17
21	Genetic variations of bone marrow mesenchymal stromal cells derived from acute leukemia and myelodysplastic syndrome by targeted deep sequencing. <i>Leukemia Research</i> , 2017, 62, 23-28.	0.8	10
22	Replenishing exosomes from older bone marrow stromal cells with miR-340 inhibits myeloma-related angiogenesis. <i>Blood Advances</i> , 2017, 1, 812-823.	5.2	75
23	Teriflunomide restores 5-azacytidine sensitivity via activation of pyrimidine salvage in 5-azacytidine-resistant leukemia cells. <i>Oncotarget</i> , 2017, 8, 69906-69915.	1.8	8
24	Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib. <i>International Journal of Molecular Sciences</i> , 2016, 17, 570.	4.1	31
25	Exosomes promote bone marrow angiogenesis in hematologic neoplasia. <i>Current Opinion in Hematology</i> , 2016, 23, 268-273.	2.5	60
26	Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely. <i>Drug Design, Development and Therapy</i> , 2014, 8, 1151.	4.3	17
27	Constitutive activation of the ATM/BRCA1 pathway prevents DNA damage-induced apoptosis in 5-azacytidine-resistant cell lines. <i>Biochemical Pharmacology</i> , 2014, 89, 361-369.	4.4	22
28	Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. <i>Blood</i> , 2014, 124, 3748-3757.	1.4	497
29	BCL2L11 (BIM) Deletion Polymorphism Is Associated with Molecular Relapse after ABL Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myeloid Leukemia with Complete Molecular Response. <i>Blood</i> , 2014, 124, 1797-1797.	1.4	3
30	Exosomes Derived from Hypoxic Leukemia Cells Enhance Tube Formation in Endothelial Cells. <i>Journal of Biological Chemistry</i> , 2013, 288, 34343-34351.	3.4	307
31	The <i>BCL2L11</i> (<i>BIM</i>) deletion polymorphism is a possible criterion for discontinuation of imatinib in chronic myeloid leukaemia patients. <i>British Journal of Haematology</i> , 2013, 160, 269-271.	2.5	15
32	Leukemia cell to endothelial cell communication via exosomal miRNAs. <i>Oncogene</i> , 2013, 32, 2747-2755.	5.9	403
33	Clinical relevance of plasma miR-106b levels in patients with chronic obstructive pulmonary disease. <i>International Journal of Molecular Medicine</i> , 2013, 31, 533-539.	4.0	51
34	Lower Plasma Mir-92a Levels Predict Shorter Progression-Free Survival In Newly Diagnosed Symptomatic Multiple Myeloma Patients. <i>Blood</i> , 2013, 122, 1879-1879.	1.4	1
35	Therapeutic Potential Of Targeting Sphingosine-1-Phosphatase and Sphingosine Kinases In Multiple Myeloma. <i>Blood</i> , 2013, 122, 1894-1894.	1.4	1
36	High Frequencies Of Switching To 2nd TKIs and Failure To Maintain Standard Imatinib Dose In Japanese CML Patients With BIM Genetic Variants. <i>Blood</i> , 2013, 122, 4021-4021.	1.4	9

#	ARTICLE	IF	CITATIONS
37	Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders. <i>Blood Cancer Journal</i> , 2012, 2, e53-e53.	6.2	66
38	The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population. <i>BMC Medical Genetics</i> , 2012, 13, 6.	2.1	14
39	Clinical Impact of Down-Regulated Plasma miR-92a Levels in Non-Hodgkin's Lymphoma. <i>PLoS ONE</i> , 2011, 6, e16408.	2.5	86
40	Detection method for quantifying global DNA methylation by fluorescence correlation spectroscopy. <i>Analytical Biochemistry</i> , 2011, 415, 145-150.	2.4	12
41	Non-random chromosomal deletion clustering at 20q in Waldenström macroglobulinemia. <i>Hematology</i> , 2011, 16, 139-142.	1.5	3
42	Plasma Mir-92a Levels in Multiple Myeloma Correlate with T-Cell-Derived Mir-92a and Restored in Bortezomib Responder. <i>Blood</i> , 2011, 118, 2871-2871.	1.4	1
43	Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a. <i>BMC Research Notes</i> , 2010, 3, 347.	1.4	55
44	Follistatin-like-1, a diffusible mesenchymal factor determines the fate of epithelium. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 4601-4606.	7.1	28
45	Reconstruction of Oviduct and Demonstration of Epithelial Fate Determination in Mice1. <i>Biology of Reproduction</i> , 2010, 82, 528-533.	2.7	41
46	Reduced fertility with impairment of early-stage embryos observed in mice lacking Lgr4 in epithelial tissues. <i>Fertility and Sterility</i> , 2010, 94, 2878-2881.	1.0	27
47	An Evidence of Stromal Cell Populations Functionally Linked with Epithelial Cell Populations in the Mouse Oviduct. <i>Zoological Science</i> , 2004, 21, 319-326.	0.7	9
48	Characterization of newly established clonal oviductal cell lines and differential hormonal regulation of gene expression. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2003, 39, 146-156.	1.5	15
49	CHARACTERIZATION OF NEWLY ESTABLISHED CLONAL OVIDUCTAL CELL LINES AND DIFFERENTIAL HORMONAL REGULATION OF GENE EXPRESSION. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2003, 39, 146.	1.5	2